

## ABBREVIATIONS

AE	Adverse event
ALP	Alkaline phosphatase
ALT	Alanine transaminase
AP	Appetite loss
AST	Aspartate transaminase
CI	Confidence interval
CF	Cognitive functioning
CO	Constipation
CR	Complete response
CT	Computed tomography
DC	Disease control
DI	Diarrhoea
DY	Dyspnoea
ECOG PS	Eastern Cooperative Oncology Group Performance Status
EF	Emotional functioning
EORTC	European Organisation for Research and Treatment of Cancer
FA	Fatigue
FAGG	Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten
FI	Financial difficulties
FU	Follow-up
GHS	Global Health Status
ID	Identifier
ITT	Intent to treat
MRI	Magnetic resonance imaging
Mo	Months
NCI CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
n-P	Nab-Paclitaxel
NV	Nausea and vomiting
OR	Overall response
ORR	Overall response rate
OS	Overall survival
PA	Pain
PD	Progressive disease
PF2	Physical functioning
PFS	Progression free survival
PR	Partial response
QOL	Quality of life
RECIST	Response evaluation criteria for solid tumors
RF	Role functioning
SAE	Serious adverse event
SD	Stable disease
SF	Social functioning
SL	Insomnia
SUSAR	Suspected unexpected serious adverse reaction
TUDD	Time to definitive deterioration
v, vs.	versus

Randomized crossover trial to assess the effects and quality of life in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel. QOLINPAC  
EudraCT # 2013-004101-75, NCT02106884

---